市場調査レポート
商品コード
1148463

大容量非経口剤の世界市場:2022年~2027年

Large Volume Parenteral Market - Forecasts from 2022 to 2027

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 137 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
大容量非経口剤の世界市場:2022年~2027年
出版日: 2022年10月10日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 137 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の大容量非経口剤の市場規模は、2020年の89億2,700万米ドルから、6.38%のCAGRで推移し、2027年末には137億6,800万米ドルの規模に成長すると予測されています。

当レポートでは、世界の大容量非経口剤の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析
  • 産業バリューチェーン分析

第5章 大容量非経口剤市場の分析:容量別

  • 100ml~250ml
  • 250ml~500ml
  • 500ml超

第6章 大容量非経口剤市場の分析:用途別

  • 電解質および体液バランスの修正
  • 栄養
  • 他の薬物を投与するための媒体

第7章 大容量非経口剤市場の分析:包装容器別

  • ガラス瓶
  • ビニール袋

第8章 大容量非経口剤市場の分析:地域別

  • 北米
  • 南米
  • 欧州
  • 中東・アフリカ
  • アジア太平洋

第9章 競合環境・分析

  • 主要企業・戦略分析
  • 新興企業・市場の収益性
  • M&A・契約・提携
  • ベンダーの競合マトリックス

第10章 企業プロファイル

  • Fresenius Kabi AG
  • Albert David Ltd.
  • Otsuka Holdings Co., Ltd.
  • Grifols S.A.
  • B. Braun Melsungen AG
  • BML Parenteral Drugs
  • Akums Drugs & Pharmaceuticals Ltd.
  • DJ Labs
  • Parenteral Drugs(India)Limited
  • BKRS Pharma Pvt. Ltd.
目次
Product Code: KSI061613637

The global market for large volume parenteral (LVP) is predicted to grow at a CAGR of 6.38% from a market size of US$8.927 billion in 2020 to achieve a market size of US$ 13.768 billion by the end of 2027.

Parenterals are referred to as the dosage forms other than the oral route of drug administration; hence the drug administration is performed by the other routes, especially intramuscular, subcutaneous, and intravenous. Large volume parenteral is delivered through an intravenous route of administration and is present in a volume greater than 100ml. These comprise 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml. accordingly, these are packaged in large amounts for use in many applications, for example, for nutrition requirements, for the correction of electrolyte & fluid balance disturbances, and as a vehicle for administering other drugs.

The growing prevalence of chronic diseases is propelling the market demand in the forecast period. The prevalence of the number of hospitalizations in a year for treating diseases requiring LVPs is burgeoning the market demand in the forecast period. In the cases of surgeries, LVPs find immense use; thus, the growing number of surgical procedures is also providing an impetus in propelling the market growth in the forecast period.

Common large volume parenterals include sodium chloride solution, dextrose solution, Ringer's solution, and lactated Ringer's solution, also the combination of dextrose and sodium chloride. The LVPs serve as a mode of faster drug delivery for patients in need, particularly at the time of surgeries; therefore are quite effective.

The growing drug delivery industry also provides strong growth prospects for the market to proliferate in the forecast period. The increasing demand of patients for single-dose vaccine administration is also fueling market growth in the forecast period.

Limited number of producers to hinder the market demand

However, there are a limited number of producers for the supply of large-volume parenteral in the United States. These shortages are due to manufacturing problems interrupting production operations in the country. It has been noticed that in spite of the high interest for large volume parenterals in the country, very few manufacturers produce these products; thus, an increased demand, along with the delay in the manufacturing of LVP, has further resulted in shortages of important LVPs in the United States of America.

Some manufacturers have discontinued the products in certain packaging formats or have withdrawn from the market altogether. According to the second report by the US Council of Science and Public Health on national drug shortages, the report stated that problems, specifically the sterile injectables, including the LVPs, with product discontinuations, accounted for over 80% of the drug shortages in 2014 and 2015. It was reported that there were shortages of sodium chloride (saline) and dextrose solutions sold in large volumes for injection.

The company, Grifols, has implemented its vertical integration strategy for a constant supply of high-quality sodium chloride 0.9% solution to the blood/plasma centers. The company stated that it would supply these large-volume parenterals in 500 ml in 2018.

The company, a Spanish pharmaceutical and chemical manufacturer is providing important LVPs to various hospitals, pharmacies, and compounding centers in the US. The production of high-quality, sterile parenteral drug products consists of complicated processes; ergo, limited manufacturers are producing parenteral goods. Grifols has a long history of producing large volume parenterals for the European region; consequently, the company has shown its capability for implementing cost-effective processes for the sustainable production of high-quality parenteral in large volumes.

The presence of cardiac diseases is fueling the market demand in the forecast period.

The growing number of people diagnosed with heart disease is one of the major drivers of the large volume parenteral market. According to the World Health Organization (WHO), 17.9 million people die each year due to cardiovascular diseases (CVDs), an estimated 31% of all deaths worldwide. Increasing consumption of tobacco, unhealthy diet and physical inactivity are raising the risk of heart attacks and strokes. According to the Centres for Disease Control and Prevention, heart disease has been the major cause of death in the United States in which coronary heart disease is the most common type of heart disease.

The rising obese population is one of the major causes ofheart attacks. According to the WHO, the worldwide prevalence of obesity nearly tripled between 1975 and 2016. All these factors are driving the demand for LVPs with use in cardiac surgeries when required across the globe, as doctors are focusing on a combination of risk factors for these diseases, implementing medical screening for individuals at risk, and then providing effective treatment to prevent disability and death while improving the quality of life. Thus, the increasing number of patients suffering from cardiovascular diseases is significantly impacting market growth positively in the forecast period.

Large volume parenterals are utilized in cardiac surgeries to prevent ischemic injury to the myocardium at the time of blood flow supply to the heart. LVPs are also used to maintain a bloodless operating field and for making myocardium flaccid, as these are electrolytic solutions where the composition is intended for maintaining diastolic arrest. Accordingly, these solutions demand administering cold to cool the myocardium and minimize activity. The solutions are slightly alkaline and hypertonic and used for compensating for metabolic acidosis and minimizing reperfusion injury occurring out of tissue edema.

COVID-19 impact overview of the global large volume parenteral market.

It has been widely observed that the ongoing global pandemic crisis is affecting the manufacturing operations of various markets worldwide. This is mainly due to the prevention measures taken by individuals to prevent transmission of the deadly viral disease. Necessary medicines as required for the treatment of critically ill patients include cardiac drugs, analgesics, anti-clotting medicines, and medical nutrition along with large volume parenteral. These are at risk of being scarce amid the novel coronavirus scenario. This is due to the soaring demand for these essential medications. Hence, the COVID-19 pandemic is projected to affect the growth of the global large volume parenteral (LVP) market negatively in 2020.

Key Developments

  • March 2022: Apisolex, a new solubility-enhancing excipient for use in parenteral medicinal formulations, has been introduced by Lubrizol Life Science (LLS) Health. This approach gets rid of solubility problems that can't be fixed by excipients or manufacturing processes currently in use.
  • January 2022: The first parenteral formulation manufacturing line at the Wuxi city site has officially begun production, according to WuXi STA, a division of WuXi AppTec. With a 2 million unit yearly capacity, this fully automated sterile production line runs in a complete isolation system. With several filling modules and an integrated lyophilizer, the automatic parenteral filling line can fill vials, syringes, and cartridges of a variety of sizes and create lyophilized powders.
  • September 2020: Clinimix (amino acids in dextrose) injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) injections, produced by baxter, have received FDA clearance in new formulations. These new Clinimix formulations make it simpler to meet patient protein objectives while providing less fluid and dextrose than previous formulations since they have the greatest protein content of any multi-chamber bag on the market in the United States, with up to 80 g/L of amino acids.

Segmentation:

  • By Volume

100 ml - 250 ml

250 ml - 500 ml

Above 500 ml

  • By Application

Correction of electrolyte & fluid balance disturbances

Nutrition

Vehicle for administering other drugs

  • By Packaging Container

Glass Bottle

Plastic Bags

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa

  • UAE
  • Israel
  • Saudi Arabia
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Market Opportunities
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of New Entrants
    • 4.4.4. Threat of Substitutes
    • 4.4.5. Competitive Rivalry in the Industry
  • 4.5. Industry Value Chain Analysis

5. Large Volume Parenteral Market Analysis, by Volume

  • 5.1. Introduction
  • 5.2. 100 ml - 250 ml
  • 5.3. 250 ml - 500 ml
  • 5.4. Above 500 ml

6. Large Volume Parenteral Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Correction of electrolyte & fluid balance disturbances
  • 6.3. Nutrition
  • 6.4. Vehicle for administering other drugs

7. Large Volume Parenteral Market Analysis, by Packaging Container

  • 7.1. Introduction
  • 7.2. Glass Bottle
  • 7.3. Plastic Bags

8. Large Volume Parenteral Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. United Arab Emirates
    • 8.5.2. Israel
    • 8.5.3. Saudi Arabia
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

  • 10.1. Fresenius Kabi AG
  • 10.2. Albert David Ltd.
  • 10.3. Otsuka Holdings Co., Ltd.
  • 10.4. Grifols S.A.
  • 10.5. B. Braun Melsungen AG
  • 10.6. BML Parenteral Drugs
  • 10.7. Akums Drugs & Pharmaceuticals Ltd.
  • 10.8. DJ Labs
  • 10.9. Parenteral Drugs (India) Limited
  • 10.10. BKRS Pharma Pvt. Ltd.